Analysts have mixed views on Axonics (NASDAQ:AXNX), with recent ratings varying from bullish to bearish. The average 12-month price target for AXNX has slightly increased to $71.29. Axonics, a medical technology company, has shown positive financial performance, including a revenue growth rate of 32.27% and a net margin of 4.22%. The company's market capitalization is below industry benchmarks, but it has demonstrated strong profitability and effective cost control.